貨號(hào)：GS40206

Ecromeximab is a human-mouse chimeric IgG1 monoclonal antibody specifically developed as a targeted immunotherapy for cancer. It is engineered to recognize and bind with high affinity to the ganglioside GD3, a specific carbohydrate antigen found on the surface of tumor cells. By leveraging the IgG1 framework, the antibody is designed to engage the human immune system effectively, primarily through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), to eliminate GD3-expressing malignant cells.